Galderma Group AG (GALD.SW) stock: key figures, P/E, revenue and dividend
Switzerland · ISIN CH1335392721
Galderma Group AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.89 bn USD | 5.24 bn USD |
| Gross profit | 3.40 bn USD | 3.61 bn USD |
| EBIT | 710.00 m USD | 875.79 m USD |
| Net income | 254.00 m USD | 641.83 m USD |
| Diluted EPS – continuing operations | 1.07 USD | 2.71 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
More stocks
- Realty Income (O)
- Elite Material Co Ltd (2383.TW)
- Keysight Technologies (KEYS)
- E.ON (EOAN.DE)
- Unimicron Technology Corp (3037.TW)
- United Overseas Bank Ltd (U11.SI)
- Autodesk (ADSK)
- Baker Hughes (BKR)
- Lonza Group AG (LONN.SW)
- Rheinmetall (RHM.DE)
- Singapore Telecommunications Ltd (Z74.SI)
- Edwards Lifesciences (EW)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.